ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1208

Stable Synovial Fluid Phenotype for Anti Citrullinated-Protein Antibodies in Established Rheumatoid Arthritis

Vijay Joshua1, Lena Israelsson2, Lars Klareskog3, Anca Catrina1 and Vivianne Malmström4, 1Department of Medicine, Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, 2Department of Medicine, Karolinska Institute, Stockholm, Sweden, 3Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden, 4Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: anti-CCP antibodies, anti-citrullinated protein/peptide antibodies (ACPA), rheumatoid arthritis (RA) and synovial cells, synovial fluid

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumamtoid Arthritis - Human Etiology and Pathogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Presence of anti citrullinated-protein antibodies (ACPA) in the peripheral blood of patients with rheumatoid arthritis is a validated disease biomarker. We have previously shown local synovial production of these antibodies in the synovial fluid of active RA. We aimed to investigate longitudinal stability of ACPA and ACPA fine specificities in SF of active established RA patients.

Methods:

A cohort of 30 RA patients (n=30) with established RA (median disease duration 11 years at inclusion) was followed up for a median of 9 years. Half of the included patients were testing positive for CCP2 ELISA in the SF when screened at one arbitrary time point and half were negative. Longitudinal SF samples of these patients (a median of 5 samples/patient, median follow-up time of 9 years) were analyzed for the presence of anti CCP2 antibodies and for fine ACPA specificities using ELISA against citrullinated forms of alpha-enolase (aa5-21; cep-1), fibrinogen (aa566-580; cit-fib573) and vimentin (aa60-75; cit-vim60-75) peptides. Cut off of these ELISAs were set at the 98th percentile, based on analysis of sera from healthy controls.

Results:

SF ACPA quantification using the CCP2 ELISA kit demonstrates a highly stable phenotype during time, with all patients selected on the basis of ACPA positivity at one time point (15/30, 100%) being positive on all tested occasions. The same was true for ACPA negative SF (15/30, 100%). Among fine specificities presence of anti citrullinated a-enolase was stable (with 5/30 positive and 25/30 negative patients on all tested occasions). Same trend was observed for antibodies against citrullinated vimentin with 25/30 patients being either positive (3) or negative (22) on all tested occasions and citrullinated fibrinogen with 28/30 patients being either positive (3) or negative (24) on all tested occasions.

Conclusion: We demonstrate that both ACPA and ACPA fine specificities have a stable phenotype in SF of patients with longstanding RA suggesting continuous local production of antibodies during disease progression.


Disclosure:

V. Joshua,
None;

L. Israelsson,
None;

L. Klareskog,

Janssen Research and Development, LLC,

;

A. Catrina,
None;

V. Malmström,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/stable-synovial-fluid-phenotype-for-anti-citrullinated-protein-antibodies-in-established-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology